Inhibition of purified recombinant reverse transcriptase from wild-type and zidovudine-resistant clinical isolates of human immunodeficiency virus type 1 by zidovudine, stavudine, and lamivudine triphosphates. Journal Article uri icon



  • Cross-resistance between zidovudine, stavudine, and lamivudine was studied, using purified recombinant reverse transcriptase from a zidovudine-susceptible and -resistant pair of clinical isolates of human immunodeficiency virus type 1. The zidovudine-resistant isolate exhibited low-level cross-resistance to both stavudine and lamivudine in drug susceptibility assays. Enzyme from the resistant isolate demonstrated reduced inhibition by zidovudine triphosphate and stavudine triphosphate and, to a lesser extent, lamivudine triphosphate. These findings provide additional evidence at the viral and enzyme level for cross-resistance between zidovudine and stavudine, and they suggest a possible effect of zidovudine resistance on susceptibility to lamivudine.

publication date

  • November 1, 2001

has subject area

has restriction

  • bronze

Date in CU Experts

  • October 1, 2013 12:09 PM

Full Author List

  • Duan C; Poticha D; Stoeckli TC; Petropoulos CJ; Whitcomb JM; McHenry CS; Kuritzkes DR

author count

  • 7

citation count

  • 5

Other Profiles

International Standard Serial Number (ISSN)

  • 0022-1899

Electronic International Standard Serial Number (EISSN)

  • 1537-6613

Additional Document Info

start page

  • 1336

end page

  • 1340


  • 184


  • 10